DGAP-News: Apricus Biosciences to Present at the Bio-Europe Spring 2011 Conference
ID: 364562
10.03.2011 15:57
---------------------------------------------------------------------------
SAN DIEGO, 2011-03-10 15:57 CET (GLOBE NEWSWIRE) --Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) today announced that Linda Smibert, Vice President,
Business Development at the Company's NexMed, USA, Inc. ('NexMed, USA')
subsidiary, will present at the Bio-Europe Spring 2011 conference in Milan,
Italy, on Wednesday, March 16th at 11:00 am CET.
The presentation will include a discussion of the Company's current worldwide
licensing and commercialization efforts for Vitaros(r), its first approved
product for erectile dysfunction, as well as a description of the further
development of the Company's four later stage products, MycoVa? for
onychomycosis, PrevOnco? for liver cancer, Femprox(r) for female sexual arousal
disorder and RayVa? for Raynaud's Syndrome. In addition, Ms. Smibert will
provide information on the Company's other eight product candidates it is
developing that utilize its proprietary NexACT(r) technology.
The Company's Vitaros(r) product for erectile dysfunction has been approved by
Health Canada and the Company is working towards identifying a licensing and
commercialization partner in that country. The Company is also currently
planning to make initial regulatory filings for the product for that indication
in Europe and the MENA (Middle Eastern and North African) countries in the
second quarter of 2011. In addition, Apricus Bio announced late in the fourth
quarter of 2010 and in the first quarter of 2011, licensing and
commercialization agreements for Vitaros(r) for erectile dysfunction in the
following countries and regions: in Italy with Bracco SpA, in the Gulf
Countries and certain countries in the Middle East with Elis Pharmaceuticals,
and in Israel and the Palestinian Territories with the Neopharm Group.
Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio,
commented on the upcoming presentation, 'We are looking forward to presenting
the progress of the Company's first approved Vitaros(r) product for erectile
dysfunction and its later stage product candidates. We are very pleased with
our Vitaros(r) licensing and commercialization efforts with our current partners
and we look forward to entering into additional agreements that will increase
the number of worldwide countries that approve the product for marketing and
sales therein. Ms. Smibert will also present an update on the progress we are
making with our later stage products that we believe will be of interest to
potential pharmaceutical company partners. Lastly, we are excited about the
pace of the development of many of our earlier stage product candidates that
utilize our NexACT(r) technology in the areas of oncology, dermatology,
anti-inflammatory, pain, anti-infectives, diabetes and cosmeceuticals, among
others, and we look forward to speaking with companies on how we can utilize
our proprietary technology to help them improve the effectiveness of their own
products, product candidates and compounds.'
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has
leveraged the flexibility of its clinically-validated NexACT(r) drug delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeuticclasses. Revenues and growth are driven from
out-licensing of this technology for the development and commercialization of
such compounds to pharmaceutical and biotechnology companies worldwide. In
addition, the Company is seeking to monetize its existing product pipeline,
including its first product, Vitaros(r), approved in Canada for the treatment of
erectile dysfunction, which is currently expected to be available on the
Canadian market in 2011, as well as compounds in development from pre-clinical
through Phase III, currently focused on sexual dysfunction, oncology,
dermatology, autoimmune, pain, anti-infectives, diabetes and cosmeceuticals
among others.
For further information on Apricus Bio, visit http://www.apricusbio.com and for
information on its subsidiaries please visit www.nexmedusa.com or
www.bio-quant.com. You can also find out more about the company by visiting
http://twitter.com/apricusbio or http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, timing for seeking foreign approvals for
Vitaros(r), timing and success of the commercial launch of Vitaros(r) in Italy, The
Gulf Countries and part of the Middle East and in Israel and the Palestinian
Territories, the potential size of the markets in each of these countries, the
ability to develop and commercialize the Company's products on its own and with
partners and the ability to meet its milestones. Readers are cautioned not to
place undue reliance on these forward-looking statements as actual results
could differ materially from the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the Company's most
recent annual report on Form 10-K, subsequent quarterly reports filed on Form
10-Q and other filings made with the SEC. Copies of these reports are available
from the SEC's website or without charge from the Company.
CONTACT: Apricus Biosciences, Inc.
Edward Cox, V.P.
Investor Relations&Corporate Development
Apricus Bio, Inc.
(858) 848-4249
ecox@apricusbio.com
Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX
10.03.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------Unternehmensinformation / Kurzprofil:
Datum: 10.03.2011 - 15:57 Uhr
Sprache: Deutsch
News-ID 364562
Anzahl Zeichen: 7726
Kontakt-Informationen:
Kategorie:
Wirtschaft (allg.)
Diese Pressemitteilung wurde bisher 163 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Apricus Biosciences to Present at the Bio-Europe Spring 2011 Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
